SIRT1 Activation Confers Neuroprotection in Experimental Optic Neuritis
Investigative Ophthalmology & Visual Science2007Vol. 48(8), pp. 3602–3602
Citations Over TimeTop 10% of 2007 papers
Abstract
SIRT1 activators provide an important potential therapy to prevent the neuronal damage that leads to permanent neurologic disability in optic neuritis and MS patients. Intravitreal administration of SIRT1 activators does not suppress inflammation in this model, suggesting that their neuroprotective effects will be additive or synergistic with current immunomodulatory therapies.
Related Papers
- → The optic nerve sheath on MRI in acute optic neuritis(2005)72 cited
- → Contrast-enhanced MRI in acute optic neuritis: relationship to visual performance. Kupersmith MJ, Alban T, Zeiffer B, Lefton D. Brain 2002;125:812–822.(2002)11 cited
- → Are PHOMS a clinical sign of optic neuritis?(2023)4 cited
- Protective mechanisms for endogenous retinal ganglion cells(2009)
- → Optic Neuritis is One Specific Explanation for an Optic Neuropathy(2020)